Revance Therapeutics (RVNC) Misses Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. COIN
4. PINS
5. RDDT
6. FSLR
7. SYK
8. DASH
9. SBUX
10. SNDK

Go back to Revance Therapeutics (RVNC) Misses Q2 EPS by 2c

Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update

August 5, 2021 4:05 PM EDT

- Q2 revenue for the RHA® Collection of dermal fillers of $17.0 million

- Aesthetic accounts increased to over 2,000 from over 1,500 in the prior quarter

- Fintech payment processing volume run-rate increased to over $500 million in Q2

- U.S. Food and Drug Administration (FDA) pre-approval inspection initiated in June, with approval of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines anticipated in second half 2021

- Conference call and webcast today at 4:30 p.m. ET

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a... More